oral GlyT1 inhibitor

Ph. III candidate in schizophrenia

10 and 25 mg PO QD efficacy in CIAS improv.

J. Pharmacol. Exp. Ther.

Boehringer Ingelheim Pharma, Biberach an der Riss, DE

iclepertin structure

Context. Iclepertin (BI 425809; Boehringer Ingelheim) is an oral glycine transporter-1 (GlyT1) inhibitor being developed for cognitive impairment associated with schizophrenia (CIAS). The ineffectiveness of currently available antipsychotic medications…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: